Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Alone vs Chemotherapy Followed by Gefitinib in Stage IIIB/IV NSCLC
NCT00144066Phase 3Completed
- Sponsor
- West Japan Oncology Group
- Start
- Jan 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West Japan Oncology Group. Primary endpoint: Overall Survival. Started Jan 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00144066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144066.